Bayer to Market Biocon's Insulin in China

July 27, 2006
BioPharm International Editors

Biocon Ltd. (Bangalore, India, www.biocon.com) has signed a licensing agreement with Bayer Healthcare LLC (www.bayerhealth.com), a subsidiary of Bayer AG (Leverkusen, Germany) for exclusive rights for its branded recombinant human insulin, Insugen, in China.

Biocon Ltd. (Bangalore, India, www.biocon.com) has signed a licensing agreement with Bayer Healthcare LLC (www.bayerhealth.com), a subsidiary of Bayer AG (Leverkusen, Germany) for exclusive rights for its branded recombinant human insulin, Insugen, in China. Biocon expects to launch Insugen in China in the first quarter of 2008, after completing all required regulatory steps for registration and local trials. China currently has an estimated 40 million diabetics, with 3,000 cases added daily.

Related Content:

News